The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
Engelfriet
C P
CP
Reesink
H W
HW
Mannucci
P M
PM
Gringeri
A
A
Ingerslev
J
J
Brettler
D B
DB
Mauser-Bunschoten
E P
EP
Negrier
C
C
Berntorp
E
E
Smith
O P
OP
Shapiro
A D
AD
D000917:Antibody Formation / Q000502:physiology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D001323:Autoantibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX